Patient-derived glioblastoma in vitro and in vivo studies of tryptophan metabolism via the kynurenine pathway
Patient-derived glioblastoma in vitro and in vivo studies of tryptophan metabolism via the kynurenine pathway
批准号:
9332670
负责人:
Anthony Guastella
金额:
$4.05万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-01 至 2019-08-31
关键词:
AHR geneAftercareApoptosisAryl Hydrocarbon ReceptorBiological AssayBrain NeoplasmsCell DeathCell LineCell ProliferationCell SurvivalCellsCerebrospinal FluidClinicalDataDevelopmentDioxygenasesDiseaseEnvironmentEnzymesFDA approvedFunctional disorderFutureGene TargetingGlioblastomaGliomaHumanImmunohistochemistryImmunosuppressive AgentsImplantIn VitroIndividualKnowledgeKynurenineLaboratoriesLigandsLinkLiteratureLuciferasesMalignant NeoplasmsMeasurementMeasuresMediatingMolecularMusNatureNeuraxisNicotinamide adenine dinucleotidePathway interactionsPatient-Focused OutcomesPatientsPharmaceutical PreparationsPharmacologyPharmacotherapyPlasmaPlayPositron-Emission TomographyProcessQuantitative Reverse Transcriptase PCRReceptor ActivationReporterResearch PersonnelRoleSerumSignal TransductionStaining methodStainsSurvival RateTP53 geneTestingTherapeutic InterventionTrainingTransforming Growth Factor betaTryptophan 2,3 DioxygenaseTryptophan Metabolism PathwayTryptophanaseTumor BiologyTumor Suppressor ProteinsTumor TissueU251UbiquitinUbiquitin-Conjugating EnzymesWestern BlottingWorkXenograft procedurearyl hydrocarbon receptor ligandcarcinogenesischemotherapyclinically relevantdesignextracellularimmortalized cellimprovedin vivoinhibitor/antagonistinnovationmalignant phenotypemetabolomicsmethyl tryptophanmouse modelneoplastic cellneurotoxicnew therapeutic targetnovelnovel therapeuticspatient populationstandard of caresubcutaneoustemozolomidetranscription factortumortumor growthtumor heterogeneitytumor microenvironmenttumorigenesis
中文摘要
胶质母细胞瘤(GBM)是中枢神经系统最常见的原发性恶性肿瘤,
目前造成了严重的临床问题。即使有积极的标准护理治疗,
GBM患者的平均生存期仅为~15个月,5年生存率低于5%。
目前,FDA批准的癌症化疗药物约有160种;然而,只有三种被批准。
用于治疗GBM患者。因此,开发新的治疗方法以
改善这些患者令人沮丧的临床结果。最近,亚当斯等人,发现
通过犬尿氨酸途径(KP)的色氨酸(TRP)代谢在脑缺血的病理生理学中起作用。
神经胶质瘤KP负责中枢神经系统中的大部分TRP代谢,
而在脑肿瘤患者中,这一通路变得高度失调。Opitz等人,发现
KP的一种代谢产物犬尿氨酸是芳香烃受体的内源性配体
(AHR)。AHR是一种通常与癌发生相关的转录因子,
通过控制细胞增殖,克隆形成,
侵袭性和TGF-β途径。AHR与p53的降解有关,
AHR的基因靶点是Ube 213,一种降解p53的E2泛素结合酶。所以我
假设GBM细胞中KP的抑制将降低AHR活化,
增加p53活性并将抑制肿瘤生长。
这一假设将在两个特定的目标测试使用我的实验室的独特的主要
患者来源的GBM细胞系和患者来源的异种移植小鼠模型。通过使用患者来源的
细胞系优于常规永生化细胞系(例如U87和U251),我们将涵盖
GBM内观察到的肿瘤异质性。我打算阐明
内源性AHR配体KYN和p53降解。初始体外药物治疗,
吲哚胺2,3-双加氧酶1(IDO 1; epacadostat)、IDO 2(tenatoprazole)、色氨酸抑制剂
2,3-双加氧酶(TDO 2; 680 C91)和AHR(CH 223191)的研究表明,泰妥拉唑和CH 223191具有
对细胞的作用最大,如通过MTT测定所测量的。进一步的研究将衡量
这些药物对p53降解以及细胞内/细胞外KYN水平的影响。免疫组
染色、蛋白质印迹和qRT-PCR将用于研究药物对KP的影响。
细胞AHR的荧光素酶报告基因将被转导到细胞中以定量测量AHR的表达。
处理和未处理细胞中的AHR活性。我将从这些细胞中选出两个最敏感的细胞系,
我的体外工作是在GBM原发性患者源性异种移植(PDX)小鼠中进行体内研究
模型皮下和原位PDX小鼠模型将用于体内药物治疗。
PDX小鼠将植入表达荧光素酶的细胞,从而允许每周
AHR活性的体内测量。我的目标1研究中最有效的两种抑制剂将
选择并测试替莫唑胺(目前的标准治疗一线化疗,
GBM)。为了测量体内TRP代谢,α-[11 C]-甲基-色氨酸(AMT)正电子发射
将在治疗前一天和治疗后一天进行断层扫描(PET)。我的工作可能会确定一个新的连接KP和p53,从而扩大了GBM肿瘤生物学的知识,并揭示新的
治疗干预的目标。
英文摘要
Glioblastomas (GBMs) are the most common primary malignancy of the central nervous system, and
currently poses a significant clinical problem. Even with aggressive standard of care treatment,
GBM patients have an average survival of only ~15 months, and a 5-year survival of less than 5%.
Currently, there are ~160 FDA-approved cancer chemotherapeutics; however, only three are approved
for treatment of GBM patients. Therefore, it is critical that novel therapeutics are developed to
improve the dismal clinical outcome of these patients. Recently, Adams, et al., discovered that
tryptophan (TRP) metabolism via the kynurenine pathway (KP) plays a role in the pathophysiology of
gliomas. The KP is responsible for majority of the TRP metabolism in the central nervous system,
and in brain tumor patients, this pathway becomes highly dysregulated. Opitz et al., discovered
that one metabolite of the KP, kynurenine, is an endogenous ligand of the aryl hydrocarbon receptor
(AHR). AHR is a transcription factor commonly associated with carcinogenesis, and its signaling
generates a malignant phenotype in gliomas via control of cell proliferation, clonogenicity,
invasiveness, and the TGF-β pathway. AHR has implications in the degradation of p53, as one of
AHR’s gene targets is Ube2l3, an E2 ubiquitin- conjugating enzyme that degrades p53. Therefore, I
hypothesize that suppression of the KP in GBM cells will decrease AHR activation, producing
increased p53 activity and will inhibit tumor growth.
This hypothesis will be tested in two specific aims using my laboratory’s unique primary
patient-derived GBM cell lines and patient-derived xenograft mouse models. By using patient-derived
cell lines over conventional immortalized cell lines (e.g. U87 and U251), we will encompass the
tumoral heterogeneity observed within GBMs. I plan to elucidate the relationship between the
endogenous AHR ligand KYN and p53 degradation. Initial in vitro drug treatments with selective
inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1; epacadostat), IDO2 (tenatoprazole), tryptophan
2,3-dioxygenase (TDO2; 680C91), and AHR (CH223191), show that tenatoprazole and CH223191 have the
greatest effect on cells, as measured by MTT assay. Further studies will measure the effect of
these drugs on p53 degradation, as well as intra/extra- cellular KYN levels. Immunohistochemical
staining, western blots, and qRT-PCR will be used to study the effect of the drugs on the KP in the
cells. A luciferase reporter for AHR will be transduced into cells to quantitatively measure the
AHR activity in treated and untreated cells. I will select the two most responsive cell lines from
my in vitro work to perform in vivo studies in GBM primary patient-derived xenograft (PDX) mouse
models. Both subcutaneous and orthotopic PDX mouse models will be used for in vivo drug treatments.
PDX mice will have the luciferase reporter-expressing cells implanted, thereby allowing for weekly
in vivo measurements of AHR activity. The two most effective inhibitors from my Aim 1 studies will
be selected and tested against temozolomide (current standard-of-care first-line chemotherapy for
GBM). To measure in vivo TRP metabolism, alpha-[11C]-methyl-tryptophan (AMT) positron emission
tomography (PET) scans will beconducted one-day pre- and one-day post-treatment. My work will likely identify a novel connection linking the KP and p53, thereby expanding the knowledge of GBM tumor biology and revealing new
targets for therapeutic intervention.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金